Q-omics provides the consensus-scored MAPK6-DT profile across patient tissues and cancer cell-line models. MAPK6-DT expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MAPK6-DT is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, MAPK6-DT RNA expression shows 17,792 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where MAPK6-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAPK6-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAPK6-DT survival associations across molecular data types. MAPK6-DT RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAPK6-DT RNA expression–survival associations across cancer types. High MAPK6-DT expression shows unfavorable associations in ACC, UVM, STAD and COAD, but favorable associations in LAML and LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MAPK6-DT RNA expression.
This table summarizes MAPK6-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MAPK6-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAPK6-DT shows lower tumor expression in THCA and KIRC and higher tumor expression in HNSC, LUSC, LIHC and PRAD. The HNSC box plot shows higher MAPK6-DT RNA expression in tumor versus normal tissue (log2 FC = +0.515, t-test p < 0.001).
This table shows molecular features associated with MAPK6-DT in patient tissues and cancer cell lines. In patient samples, MAPK6-DT shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
